GlassScriptPhysician profile
Amanda Elise Lipsitt
NPI 1194145300
$2,608.93
in general payments reported to CMS, 2019-2025
19 companies · $792 in 2025
The $792 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2022: $133 · 2023: $614 · 2024: $743 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.38 |
| Education | $100.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $679.83 | 2019-2025 | |
| Genetix Biotherapeutics INC | $415.81 | 2024-2025 | Lyfgenia |
| Novartis Pharmaceuticals Corporation | $339.01 | 2024-2025 | |
| Sobi, INC | $281.19 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $171.74 | 2023-2024 | |
| Pharming Healthcare, INC. | $149.10 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $127.80 | 2023 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $122.95 | 2019-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $120.44 | 2019 | |
| Daiichi Sankyo INC. | $28.69 | 2024 | Vanflyta |
| Incyte Corporation | $26.12 | 2025 | Niktimvo |
| Photocure INC | $23.88 | 2019 | |
| Mesoblast, INC. | $23.87 | 2025 | Ryoncil |
| Novo Nordisk INC | $22.57 | 2019 | |
| Syndax Pharmaceuticals, INC. | $20.56 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $19.45 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $18.65 | 2022 | |
| Karl Storz Endoscopy-America | $17.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lipsitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.